The FORWARD Study
An open-label study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of a single dose of tanruprubart (ANX005) in participants with Guillain-Barré Syndrome (GBS).
The FORWARD Study
An open-label study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of a single dose of tanruprubart (ANX005) in participants with Guillain-Barré Syndrome (GBS).
What is Guillain-Barré Syndrome?
- Guillain-Barré Syndrome (GBS) is a rare and serious condition in which the body's defense system (immune system) damages nerves.
- GBS often follows an infection, but it can rarely happen to anyone, anywhere and at any time.
Current Treatments for GBS
Standard GBS treatments – intravenous immunoglobulin (IVIg) and plasma exchange (PE) – are not approved by the FDA for patients diagnosed with Guillain-Barré Syndrome.
We do not have a clear understanding how these treatments work. They are thought to help with recovery.
What is Guillain-Barré Syndrome?
Guillain-Barré Syndrome is a rare and serious condition in which the body’s defense system (immune system) damages nerves.
GBS often follows an infection, but it can rarely happen to anyone, anywhere and at any time.
Current Treatments for GBS
Current GBS treatments – intravenous immunoglobulin (IVIg) and plasma exchange (PE) – are not approved by the FDA for patients diagnosed with Guillain-Barré Syndrome.
We do not have a clear understanding how these treatments work. They are thought to help speed up recovery.
What is Tanruprubart?
Tanruprubart (ANX005) is an investigational drug being studied in patients diagnosed with GBS. It is not yet approved by the FDA or any other healthcare authority.
What is Tanruprubart?
Tanruprubart (ANX005) is an investigational drug being studied in patients diagnosed with GBS. It is not yet approved by the FDA or any other healthcare authority.
Tanruprubart is still being studied for side effects. It may have an effect on the immune system. The study doctor will discuss the potential benefits and risks of the study with you.
Tanruprubart has been studied in a previous study to test whether it works and is safe in patients diagnosed with Guillain-Barré Syndrome.
Tanruprubart still being studied for side effects. It may have an effect on the immune system. The study doctor will discuss the potential benefits and risks of the study with you.
Tanruprubart has been studied in a previous study to test whether it works and is safe in patients diagnosed with Guillain-Barré Syndrome.
Tanruprubart has been studied in over 200 patients with GBS
In a previous study, more than 200 people diagnosed with Guillain-Barré Syndrome received a dose of tanruprubart or placebo. A placebo is a treatment that has no active drug.
In this study, more than 85% of patients who received the dose of tanruprubart being tested in the FORWARD study showed improvements in muscle strength and function as early as the first week compared to about 50% of patients who received the placebo.
The most common side effects in this study were reactions related to the infusion. These side effects were typically a rash. Some participants experienced an increased heart rate or a drop in blood pressure, which got better with treatment.
Tanruprubart has been studied in over 200 patients with GBS
In a previous study, more than 200 people diagnosed with Guillain-Barré Syndrome received a dose of tanruprubart or placebo. A placebo is a treatment that has no active drug.
In this study, more than 85% of patients who received the dose of tanruprubart being tested in the FORWARD study showed improvements in muscle strength and function as early as the first week compared to about 50% of patients who received the placebo.
The most common side effects in this study were reactions related to the infusion. These side effects were typically a rash. Some participants experienced an increased heart rate or a drop in blood pressure, which got better with treatment.
About the FORWARD Study
The FORWARD study is an open-label study in North America and Europe. The study has been reviewed and approved for ethics and safety. All patients will receive tanruprubart. The purpose of this study is to better understand tanruprubart’s effects by collecting information such as:
- What happens to it in the body
- How it affects Guillain-Barré Syndrome
- How well it may work and is tolerated
Patients will be in the study for about 6 months. Patients can change their minds and leave the study at any time.
About the FORWARD Study
The FORWARD study is an open-label study in North America and Europe. The study has been reviewed and approved for ethics and safety. All patients will receive tanruprubart. The purpose of this study is to better understand tanruprubart’s effects by collecting information such as:
- What happens to it in the body
- How it affects Guillain-Barré Syndrome
- How well it may work and is tolerated
Patients will be in the study for about 6 months. Patients can change their minds and leave the study at any time.
Study Tests and Assessments
Patients in the FORWARD study will undergo the following tests and assessments::
- Questions about your past and current health
- Questions about how you are feeling
- Tests of muscle strength
- Physical exams
- Heart health tests
- Blood and urine tests
Study Tests and Assessments
Patients in the FORWARD study will undergo the following tests and assessments::
- Questions about your past and current health
- Questions about how you are feeling
- Tests of muscle strength
- Physical exams
- Heart health tests
- Blood and urine tests
Are You Interested in Participating in the FORWARD Study?
If you are 12 to 85 years of age and have been diagnosed with Guillain-Barré Syndrome in the last 5-10 days, you could be eligible for this study.
If you have any questions or require further information, please speak to your doctor. They can tell you more about the study drug and the FORWARD study
The FORWARD Study
An open-label study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of a single dose of tanruprubart (ANX005) in participants with Guillain-Barré Syndrome (GBS).
What is Guillain-Barré Syndrome?
Guillain-Barré Syndrome is a rare and serious condition in which the body’s defense system (immune system) damages nerves.
GBS often follows an infection, but it can rarely happen to anyone, anywhere and at any time.
Current Treatments for GBS
Current GBS treatments – intravenous immunoglobulin (IVIg) and plasma exchange (PE) – are not approved by the FDA for patients diagnosed with Guillain-Barré Syndrome.
We do not have a clear understanding how these treatments work. They are thought to help speed up recovery.
What is Tanruprubart?
Tanruprubart (ANX005) is an investigational drug being studied in patients diagnosed with GBS. It is not yet approved by the FDA or any other healthcare authority.
Tanruprubart has been studied in over 200 patients with GBS
In a previous study, more than 200 people diagnosed with Guillain-Barré Syndrome received a dose of tanruprubart or placebo. A placebo is a treatment that has no active drug.
In this study, more than 85% of patients who received the dose of tanruprubart being tested in the FORWARD study showed improvements in muscle strength and function as early as the first week compared to about 50% of patients who received the placebo.
The most common side effects in this study were reactions related to the infusion. These side effects were typically a rash. Some participants experienced an increased heart rate or a drop in blood pressure, which got better with treatment.
About the FORWARD Study
The FORWARD study is an open-label study in North America and Europe. The study has been reviewed and approved for ethics and safety. All patients will receive tanruprubart. The purpose of this study is to better understand tanruprubart’s effects by collecting information such as:
- What happens to it in the body
- How it affects Guillain-Barré Syndrome
- How well it may work and is tolerated
Patients will be in the study for about 6 months. Patients can change their minds and leave the study at any time.
Study Tests and Assessments
Patients in the FORWARD study will undergo the following tests and assessments::
- Questions about your past and current health
- Questions about how you are feeling
- Tests of muscle strength
- Physical exams
- Heart health tests
- Blood and urine tests
Are You Interested in Participating in the FORWARD Study?
If you are 12 to 85 years of age and have been diagnosed with Guillain-Barré Syndrome in the last 5-10 days, you could be eligible for this study.
If you have any questions or require further information, please speak to your doctor. They can tell you more about the study drug and the FORWARD study
Locate a Site Near You
Enter your zip/postal code below to find a list of your closest treating sites.
Locate a Site Near You
Enter your zip/postal code below to find a list of your closest treating sites.